查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848613

患者來源異質骨移植/PDX模型市場按類型、腫瘤類型、研究類型、移植方法、應用和最終用戶分類——2025-2032年全球預測

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，患者來源異質骨移植/PDX 模型市場將成長至 11.1282 億美元，複合年成長率為 12.65%。

主要市場統計數據
基準年 2024 4.2904億美元
預計年份：2025年 4.8065億美元
預測年份：2032年 1,112,820,000 美元
複合年成長率 (%) 12.65%

本書權威地介紹了患者來源的異種移植（PDX）模型、其轉化意義及其在臨床前腫瘤學研究中不斷演變的作用。

患者來源的異質骨移植模型在轉化腫瘤學中日益重要，因為它們能夠保留患者的腫瘤結構、細胞異質性以及相關的微環境相互作用。透過將新鮮的人類腫瘤組織塊移植到免疫力缺乏的囓齒動物體內，研究人員可以獲得保留分子特徵和藥物反應模式、更能代表臨床疾病的模型。這種高度的相似性是PDX在藥物療效測試、作用機制研究和生物標記開發中效用的基礎，從而連接了臨床前試驗和臨床假設。

儘管PDX平台具有諸多優勢，但也面臨獨特的操作和科學研究挑戰。由於移植成功率取決於腫瘤類型和樣本質量，因此需要精細的組織處理、最佳化的移植方法以及嚴格的品管基因型鑒定以防止基因漂移。此外，出於倫理考量和法律規範，必須確保人源材料的可追溯性並遵守人道動物照護標準。因此，整合手術取得、病理檢查、分子分析和動物飼養的多學科工作流程對於充分發揮PDX系統的轉化潛力至關重要。

隨著這一領域的發展，研究人員必須權衡PDX的生物學相關性與成本、通量和可重複性等限制因素。最具影響力的項目將把標準化方案與詳細的分子註釋相結合，從而實現不同隊列間的對照比較，並加速將臨床前訊號轉化為可操作的臨床策略。

從先進的分子分析到新型移植技術和協作資料框架，技術和策略曲折點正在塑造PDX生態系統。

在技​​術創新與學術界、生物製藥公司和委外研發機構策略重點轉變的共同推動下，PDX模型領域正經歷變革。高解析度分子工具，例如單細胞定序和全面的基因組分析，如今已常規應用於PDX隊列，使研究人員能夠揭示腫瘤內異質性並追蹤不同傳代過程中抗藥性亞克隆的變化。同時，基因組工程和人源化免疫系統模型正在拓展PDX模型的生物學背景，尤其是在免疫腫瘤學應用方面。

在營運層面，已發生顯著轉變，從孤立的內部項目轉向整合生物樣本庫、分子表徵和縱向體內試驗的綜合平台。這種整合因對原位移植和複雜移植策略日益成長的需求而得到加強，這些策略旨在更好地模擬腫瘤-基質相互作用和轉移行為。同樣重要的是，數位基礎設施和資料共用框架正在日趨成熟，從而能夠進行跨中心的比較分析，並支持進行隊列研究的合作方法。

這些轉變將提升PDX模型的轉化價值，同時重塑服務模式、夥伴關係結構與競爭動態。那些將技術嚴謹性與可互通的資料實踐和標靶化的臨床轉換管道結合的機構，將定義下一代臨床前風險規避策略。

美國近期於2025年實施的關稅將如何改變PDX供應鏈、採購經濟以及整個臨床前測試生態系統的策略採購決策？

2025年的關稅環境為依賴全球供應鏈維持其PDX計畫的機構帶來了一系列新的營運考量。關稅主導進口實驗室設備、專用耗材和某些動物品系的到岸成本上漲，加速了採購審查進程，迫使許多機構重新評估籌資策略。這促使研究團隊和採購專家重新評估外部供應商的總擁有成本，並更重視前置作業時間和海關相關因素帶來的不確定性。

因此，一些研究機構正在加快對國內育種和冷凍保存能力的投資，以降低跨境關稅和物流中斷的風險。這種近岸外包趨勢能夠更好地控制遺傳完整性和族群健康，但也需要資金投入、擴大設施容量和提升營運專業水準。同時，能夠提供可替代以往進口試劑和設備的本地供應商也迎來了新的機遇，使實驗室能夠在控制採購風險的同時，維持實驗的連續性。

事實上，關稅情勢也加強了法律、監管和採購團隊之間的合作，以確保在遵守科學時間表的同時實現合規。跨國和跨境合作擴大在合作夥伴之間協商風險共用通訊協定和緊急計畫，以減輕關稅相關的延誤和價格波動對其營運的影響。最終，這些累積效應促使各方轉向加強供應鏈韌性、策略性庫存管理和供應商資格認證通訊協定。

針對不同模型類型、腫瘤類別、檢測方式、移植方法和最終用戶需求，細分市場的具體表現和策略要務。

對細分市場的詳細分析揭示了不同模型類型、腫瘤類別、研究模式、移植方法、應用領域和最終用戶之間存在的差異化需求和性能促進因素。小鼠和大鼠模型之間的模型類型差異，包括移植率、免疫相容性以及對特定外科手術或原位移植的適用性，會影響實驗設計，從而為療效或轉移研究的選擇標準提供基礎。消化器官系統、婦科、血液學、呼吸系統和泌尿器官系統類別內部的腫瘤異質性會影響檢體的可用性、移植傾向以及解讀轉化訊號所需的分子註釋程度。

體外、離體或體內測試方法的選擇決定了PDX資源的利用方式。離體和體外試驗透過機制闡明和中型通量篩檢，對體內療效測試起到補充作用，而體內測試對於藥物動力學和腫瘤微環境評估至關重要。植入方法（異位、原位或皮下）的選擇直接影響轉化相關性和通量考量。原位植入通常能獲得更具臨床意義的轉移和微環境表現型，而皮下植入則可實現更高的通量和標準化測量。

這些應用涵蓋基礎癌症研究、生物標記發現、基因組和分子研究、個人化醫療、臨床前藥物評估以及腫瘤微環境分析，每項應用都有其獨特的數據、註釋和樣本處理要求。最後，包括學術研究機構、癌症研究中心和製藥生物技術公司在內的最終用戶在通量、監管可追溯性和商業性保密性方面有著不同的優先事項，從而塑造了整個生態系統的服務模式和夥伴關係結構。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和競爭地位如何影響市場准入、監管和研究夥伴關係

區域動態對PDX資源的取得、監管預期和合作研究網路有顯著影響。美洲地區擁有高度集中的轉化腫瘤學專業知識、密集的學術中心和生物技術公司網路，並務實地致力於將PDX模型整合到臨床轉化流程中。這種環境有利於臨床前訊號與早期臨床試驗之間的快速迭代，同時也推動了對可靠的分子註釋和高品質生物檢體的需求。

歐洲、中東和非洲的監管環境各不相同，但都擁有廣泛的公共研究基礎設施。廣泛地區合作和聯盟是協調人體組織使用和動物福利標準以及匯集罕見腫瘤資源的常用機制。此類夥伴關係通常優先考慮標準化操作規程和跨中心檢驗，以確保多中心臨床前計畫具有較高的外部效度。

亞太地區產能快速擴張，國內實驗室設備和動物模型供應商數量不斷增加。對本地繁殖設施的投資，以及在特定腫瘤適應症領域強勁的臨床研究活動，使該地區成為服務市場和新型患者來源材料的來源。在所有地區，監管的一致性、數據的互通性和供應商合格都是提高PDX研究可重複性和實用性的關鍵因素。

在PDX模型格局中，企業定位、聯盟模式和能力投資共同決定了相關人員之間的競爭優勢。

在PDX（病患來源異種移植）研究領域，各機構之間的競爭動態日益受到能力廣度、分子註釋深度以及提供端到端轉化服務能力的影響。領先的研發機構和科研計畫正投資於整合生物樣本庫、基因組表徵和縱向體內試驗的綜合服務，以縮短藥物研發公司的決策週期。學術中心與商業實驗室之間的策略夥伴關係，在擴大獲取註釋豐富的隊列資料的同時，也分攤了模型維護的成本和營運負擔。

另一個值得關注的趨勢是數據資產的優先化。能夠整合可互通的分子、表現型和治療反應資料集的機構，可以進行比較分析和預測建模，從而創造差異化價值。同時，那些擁有嚴格的品管流程和透明的人類來源樣本來源的機構，能夠確保獲得監管機構和倫理監督機構的信任。此外，提供可擴展的原位建模、免疫人源化和專業移植技術的供應商，正在開闢與特定治療模式（例如免疫腫瘤學或轉移性疾病治療）相契合的利基市場。

總而言之，這些策略舉措凸顯了PDX領域的競爭優勢在於那些能夠將科學嚴謹性、營運可擴展性和強大的資料管理能力結合起來的人。

為產業領導者提供實際、影響深遠的行動方案，以增強供應鏈韌性、加速轉化價值並最佳化臨床前試驗結果

產業領導者可以採取以下幾項具體措施來增強轉換應用的影響力和營運韌性。首先，優先投資國內族群管理和冷凍保存基礎設施，以維持遺傳完整性，同時減少跨境干擾。其次，將組織獲取、移植和分子表徵的統一通訊協定製度化，以提高可重複性並實現有意義的隊列間比較。第三，將全面的基因組和單細胞分析整合到基準表徵工作流程中，以便在分子層次上解讀體內訊號。

第四，我們將與專業供應商建立策略夥伴關係，以便在無需承擔資本和營運成本的情況下，取得他們在同位素和人源化模型方面的專業知識。第五，我們將採用聯邦資料架構和標準化元資料模式，以促進各研究機構間安全的資料共用和比較分析。第六，我們將積極與監管機構和倫理委員會溝通，履行合規義務，並為轉化研究建立切實可行的人體組織使用和動物福利框架。最後，我們將開發支援轉換終點的商業模式，提供包括生物銀行、分子註釋、體內測試和資料提供在內的捆綁式服務，從而減少使用者操作障礙，加快決策速度。

採用透明、多學科的研究途徑，結合主要相關人員訪談、技術檢驗和結構化證據綜合，確保分析的嚴謹性。

本研究綜合分析採用多學科方法，整合了來自同行評審文獻、方案庫以及對轉化科學家、實驗室人員、採購專家和合約研究組織（CRO）高管的結構化訪談的證據。主要資料透過半結構化訪談收集，以了解實際營運、痛點和策略重點，並將這些定性見解與技術文獻和程序標準檢驗，以確保科學準確性。

此外，我們還進行了一項技術檢驗，審查了具有代表性的PDX方案和標註方法，以評估可重複性風險和資料互通性。我們採用分割方法，將模型類型、腫瘤類別、研究模式、移植方法、應用領域和最終用戶畫像進行映射，明確功能需求和服務缺口。在整個過程中，我們進行了品質保證檢查，以確認所引用方法的來源以及所參考的監管和倫理指南的時效性。

這些進展包括對持續技術發展和不斷變化的政策環境的敏感性。因此，本研究強調可調整的建議，並鼓勵定期重新評估。此調查方法框架可支持可重複的更新，並且可以進行調整以納入新的原始數據，以及對特定腫瘤類型和地理的更深入研究。

全面深入了解決定PDX舉措近期發展軌跡和轉化成功的科學、營運和政策因素。

摘要：當患者來源的異種移植模型被整合到嚴謹的分子表徵流程中，並由穩健的運作系統進行管理時，它們仍然是轉化腫瘤學的基石。單細胞分析、免疫人源化和原位建模的科學進步正在提高PDX平台的轉化保真度，而供應鏈壓力和採購經濟的變化正在促使策略轉向國內能力建設和區域夥伴關係。

為了充分發揮PDX方法的潛力，相關人員必須權衡生物學相關性與通量、成本和可重複性等因素。標準化通訊協定、可互通的資料實踐以及能夠分擔基礎設施負擔的協作模式將是這項工作的核心。最終，那些能夠將卓越的技術與策略供應鏈計劃和清晰的轉化路徑相結合的機構，將最有能力將臨床前研究成果轉化為臨床成功。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人源化免疫系統整合到PDX模型中，以最佳化免疫治療反應
  • 透過在PDX模型中應用CRISPR基因編輯技術加速個人化腫瘤藥物篩檢
  • 採用高通量自動化PDX平台進行大規模臨床前藥物評價
  • 生物製藥公司和合約研究組織 (CRO) 合作，以實現 PDX 模型品管和可重複性的標準化。
  • 發展類器官衍生的異種移植模型以補充異質性腫瘤的PDX研究
  • 利用PDX模型中的多組體學分析鑑定標靶治療的預測性生物標記
  • 擴大PDX生物樣本庫，納入不同種族和罕見癌症亞型，以供全球研究使用。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 病人來源異質骨移植/PDX模型市場（按類型分類）

  • 小鼠模型
  • 大鼠模型

9. 依腫瘤類型分類的病人來源異質骨移植/PDX模型市場

  • 消化器官系統
  • 婦科
  • 血液學
  • 呼吸系統
  • 泌尿系統

10. 依研究類型分類的病人來源異質骨移植/PDX模型市場

  • 體外
  • 體外
  • 體內

11. 依移植方法分類的病人來源異質骨移植/PDX模型市場

  • 異位
  • 共形主題
  • 皮下

12. 按應用分類的患者來源異質骨移植/PDX模型市場

  • 基礎癌症研究
  • 生物標記發現
  • 基因組和分子研究
  • 個人化醫療
  • 臨床前藥物評價
  • 腫瘤微環境分析

13. 依最終使用者分類的病患來源異質骨移植/PDX模型市場

  • 學術研究機構
  • 癌症研究中心
  • 製藥和生物技術公司

14. 各地區病患來源異質骨移植/PDX模型市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 病人來源異質骨移植/PDX模型市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國患者來源異質骨移植移植/PDX模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abnova Corporation
    • Altogen Labs
    • Biocytogen
    • BioDuro LLC
    • BioReperia AB
    • Certis Oncology Solutions
    • Champions Oncology, Inc.
    • Charles River Laboratories International, Inc.
    • Creative Animodel
    • Creative Biolabs
    • Crown Bioscience by JSR Corporation
    • EPO Berlin-Buch GmbH
    • GemPharmatech Co. Ltd.
    • Genesis Drug Discovery & Development
    • Hera Biolabs
    • HOIST Co.,Ltd.
    • InnoSer
    • Inotiv, Inc.
    • Laboratory Corporation of America Holdings
    • LIDE Shanghai BIoTech, Ltd
    • Mediford Corporation by PHC Holdings Corporation
    • Oncodesign Services
    • Shanghai ChemPartner
    • Shanghai Medicilon Inc.
    • TheraIndx Lifesciences Pvt. Ltd.
    • Urosphere SAS
    • WuXi AppTec Co., Ltd.
    • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market is projected to grow by USD 1,112.82 million at a CAGR of 12.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 429.04 million
Estimated Year [2025] USD 480.65 million
Forecast Year [2032] USD 1,112.82 million
CAGR (%) 12.65%

An authoritative primer on patient-derived xenograft (PDX) models, their translational relevance, and evolving role in preclinical oncology research

Patient-derived xenograft models are increasingly central to translational oncology as they preserve patient tumor architecture, cellular heterogeneity, and relevant microenvironmental interactions that are often lost in long-established cell lines. By engrafting fresh human tumor fragments into immunocompromised rodents, researchers obtain models that retain molecular signatures and drug response patterns more representative of clinical disease. This fidelity underpins their utility across drug efficacy testing, mechanism-of-action studies, and biomarker development, providing a bridge between preclinical exploration and clinical hypotheses.

Despite their strengths, PDX platforms present distinct operational and scientific challenges. Engraftment success varies by tumor type and specimen quality, requiring refined tissue handling, optimized implantation methods, and rigorous quality-control genotyping to guard against drift. Moreover, ethical considerations and regulatory oversight demand traceability of human-derived materials and adherence to humane animal care standards. Consequently, multidisciplinary workflows that integrate surgical retrieval, pathology review, molecular profiling, and animal husbandry are essential to realize the translational promise of PDX systems.

As the field advances, investigators must balance the high biological relevance of PDX with cost, throughput, and reproducibility constraints. The most impactful programs are those that combine standardized protocols with deep molecular annotation, enabling controlled comparisons across cohorts and accelerating the translation of preclinical signals into actionable clinical strategies.

Technical and strategic inflection points reshaping the PDX ecosystem from advanced molecular profiling to novel engraftment techniques and collaborative data frameworks

The PDX landscape is undergoing transformative shifts driven by converging technological innovations and changing strategic priorities across academia, biopharma, and contract research organizations. High-resolution molecular tools such as single-cell sequencing and comprehensive genomic profiling are now routinely layered onto PDX cohorts, enabling researchers to dissect intratumoral heterogeneity and trace resistant subclones across passages. Concurrently, genome engineering and humanized immune system models are expanding the biological contexts in which PDX models can be interrogated, particularly for immuno-oncology applications.

Operationally, there is a pronounced move from isolated in-house programs toward integrated platforms that combine biobanking, molecular characterization, and longitudinal in vivo testing. This integration is reinforced by increased demand for orthotopic engraftment and sophisticated implantation strategies that better recapitulate tumor-stroma interactions and metastatic behavior. Equally important, digital infrastructure and data-sharing frameworks are maturing, allowing comparative analyses across institutions and enabling federated approaches to cohort discovery.

Together, these shifts amplify the translational value of PDX models while reshaping service models, partnership structures, and competitive dynamics. Organizations that align technical rigor with interoperable data practices and targeted clinical translation pathways will define the next generation of preclinical de-risking strategies.

How recent United States tariffs in 2025 are altering PDX supply chains, procurement economics, and strategic sourcing decisions across the preclinical ecosystem

The tariff environment introduced in 2025 has created a new set of operational considerations for organizations that rely on global supply chains to maintain PDX programs. Tariff-driven increases in the landed cost of imported laboratory equipment, specialized consumables, and certain animal strains have accelerated procurement reviews and prompted many groups to reevaluate sourcing strategies. In response, research teams and procurement specialists are reassessing the total cost of ownership for external suppliers and increasing scrutiny of lead times and customs-related variability.

Consequently, some institutions are accelerating investments in domestic breeding and cryopreservation capacity to reduce exposure to cross-border tariffs and logistic disruptions. This nearshoring trend enhances control over genetic integrity and colony health, but it requires capital allocation, expanded facility capability, and operational expertise. At the same time, there are emerging opportunities for regional vendors that can offer validated alternatives to previously imported reagents and equipment, enabling laboratories to maintain experimental continuity while managing procurement risk.

Practically, the tariff landscape has also intensified collaboration between legal, regulatory, and procurement teams to ensure compliance while preserving scientific timelines. For multinational studies and cross-border collaborations, partners are increasingly negotiating shared risk protocols and contingency plans to mitigate the operational impact of tariff-related delays and price volatility. Ultimately, the cumulative effect is a reorientation toward supply chain resilience, strategic inventory management, and strengthened supplier qualification protocols.

Segment-specific performance and strategic imperatives across model types, tumor categories, study modalities, implantation approaches and end-user demands

A granular view of segmentation reveals differentiated needs and performance drivers across types of models, tumor classes, study modalities, implantation approaches, applications, and end users. Model type distinctions between Mice Models and Rat Models shape experimental design through differences in engraftment rates, immune compatibility, and suitability for specific surgical or orthotopic procedures, thereby informing selection criteria for efficacy or metastasis studies. Tumor heterogeneity across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological categories influences specimen availability, engraftment propensity, and the degree of molecular annotation required to interpret translational signals.

Study type choices among Ex-vivo, In-vitro, and In-vivo modalities determine how PDX resources are leveraged: ex-vivo and in-vitro assays complement in-vivo efficacy testing by enabling mechanistic interrogation and medium-throughput screening, while in-vivo studies remain essential for pharmacokinetic and tumor microenvironment assessments. Implantation method selection-whether Heterotopic, Orthotopic, or Subcutaneous-directly impacts translational relevance and throughput considerations; orthotopic approaches often yield more clinically relevant metastatic and microenvironmental phenotypes, while subcutaneous implants can offer higher throughput and standardized measurement.

Applications span Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis, each imposing unique data, annotation, and sample handling requirements. Finally, end users such as Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies bring divergent priorities around throughput, regulatory traceability, and commercial confidentiality, which in turn shape service models and partnership structures across the ecosystem.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa and Asia-Pacific influencing access, regulation and research partnerships

Regional dynamics are exerting a strong influence on access to PDX resources, regulatory expectations, and collaborative networks. In the Americas, there is significant concentration of translational oncology expertise, dense networks of academic centers and biotechs, and a pragmatic focus on integrating PDX models into clinical translational pipelines. This environment supports fast iteration between preclinical signals and early-phase clinical testing, while simultaneously driving demand for robust molecular annotation and high-quality biobanked specimens.

Europe, Middle East & Africa feature a heterogeneous regulatory landscape and a broad range of public research infrastructures. Pan-regional collaborations and consortia are common mechanisms to harmonize standards for human tissue use and animal welfare, and to pool rare tumor resources. These partnerships often prioritize standardized operating procedures and cross-site validation to enable multi-center preclinical programs with higher external validity.

The Asia-Pacific region combines rapid capacity expansion with growing domestic suppliers of laboratory equipment and animal models. Investment in local breeding facilities, coupled with strong clinical research activity in specific oncology indications, positions the region as both a market for services and a source of novel patient-derived material. Across all regions, regulatory alignment, data interoperability, and supplier qualification remain critical enablers of reproducible and translatable PDX-based research.

Corporate positioning, partnership patterns, and capability investments that define competitive advantage among stakeholders in the PDX model landscape

Competitive dynamics among organizations involved in PDX research are increasingly shaped by capability breadth, depth of molecular annotation, and the ability to offer end-to-end translational services. Leading providers and institutional programs are investing in integrated offerings that combine biobanking, genomic characterization, and longitudinal in vivo testing to shorten decision cycles for drug developers. Strategic partnerships between academic centers and commercial laboratories are expanding access to richly annotated cohorts while distributing the cost and operational burden of model maintenance.

Another salient trend is the prioritization of data assets. Entities that can aggregate interoperable molecular, phenotypic, and treatment-response datasets create differentiated value by enabling comparative analyses and predictive modeling. At the same time, organizations that demonstrate rigorous quality-control pipelines and transparent provenance for human-derived materials secure trust from regulatory and ethical oversight bodies, which is increasingly material in commercial collaborations. Additionally, vendors that offer scalable orthotopic modeling, immune humanization, or specialized implantation expertise are carving niche positions that align with specific therapeutic modalities, such as immuno-oncology or metastasis-focused programs.

Collectively, these strategic moves underscore that competitive advantage in the PDX domain accrues to those who combine scientific rigor with operational scalability and robust data stewardship.

Practical, high-impact actions for industry leaders to strengthen supply resilience, accelerate translational value and optimize preclinical study outcomes

Industry leaders can take several concrete steps to enhance translational impact and operational resilience. First, prioritize investments in domestic colony management and cryopreservation infrastructure to reduce exposure to cross-border disruptions while preserving genetic fidelity. Second, institutionalize harmonized protocols for tissue procurement, implantation, and molecular characterization to improve reproducibility and enable meaningful cross-cohort comparisons. Third, integrate comprehensive genomic and single-cell profiling into baseline characterization workflows so that in vivo signals can be interpreted in a molecularly informed context.

Fourth, cultivate strategic partnerships with specialized providers to access orthotopic and humanized model expertise without bearing full capital and operational overhead. Fifth, adopt federated data architectures and standardized metadata schemas to facilitate secure data sharing and comparative analyses across institutions. Sixth, engage proactively with regulatory and ethical authorities to shape pragmatic frameworks for human tissue use and animal welfare that support translational research while meeting compliance obligations. Finally, align commercial models to support translational endpoints-offering bundled services that encompass biobanking, molecular annotation, in vivo testing, and data delivery-to reduce friction for end-users and accelerate decision-making.

Transparent multidisciplinary research approach integrating primary stakeholder interviews, technical validation, and structured evidence synthesis to ensure analytic rigor

This research synthesis is grounded in a multidisciplinary methodology that triangulates evidence from peer-reviewed literature, protocol repositories, and structured interviews with translational scientists, lab directors, procurement specialists, and CRO executives. Primary data were gathered through semi-structured interviews to capture operational realities, pain points, and strategic priorities, and these qualitative insights were validated against technical publications and procedural standards to ensure scientific accuracy.

In addition, technical validation exercises reviewed representative PDX protocols and annotation practices to assess reproducibility risk and data interoperability. The segmentation approach mapped model types, tumor classes, study modalities, implantation methods, applications, and end-user profiles to identify distinct capability requirements and service gaps. Throughout the process, quality assurance checks were performed to confirm the provenance of cited methods and the currency of regulatory and ethical guidance referenced.

Limitations include sensitivity to ongoing technological developments and evolving policy landscapes, which is why the research emphasizes adaptive recommendations and encourages periodic reassessment. The methodological framework supports reproducible updating and can be tailored to incorporate new primary data or targeted deep dives on specific tumor types or geographies.

Consolidated insights synthesizing scientific, operational and policy factors that will determine the near-term trajectory and translational success of PDX initiatives

In summary, patient-derived xenograft models remain a cornerstone of translational oncology when they are embedded within rigorous molecular characterization pipelines and managed through resilient operational systems. Scientific advances in single-cell analytics, immune humanization, and orthotopic modeling are enhancing the translational fidelity of PDX platforms, while supply chain pressures and changing procurement economics are prompting strategic shifts toward domestic capability building and regional partnerships.

To realize the full potential of PDX approaches, stakeholders must balance the need for high biological relevance with considerations of throughput, cost, and reproducibility. Standardized protocols, interoperable data practices, and collaborative models that distribute infrastructure burdens will be central to this effort. Ultimately, the organizations that align technical excellence with strategic supply chain planning and clear translational pathways will be best positioned to convert preclinical insights into clinical success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of humanized immune system mice in PDX models to optimize immunotherapy responses
  • 5.2. Application of CRISPR gene editing in PDX models to accelerate personalized oncology drug screening
  • 5.3. Adoption of high-throughput automated PDX platforms for large-scale preclinical drug evaluation
  • 5.4. Collaboration between biopharma and CROs to standardize PDX model quality control and reproducibility
  • 5.5. Development of organoid-derived xenograft models to complement PDX studies in heterogenous tumors
  • 5.6. Use of multi-omics profiling in PDX models to identify predictive biomarkers for targeted therapies
  • 5.7. Expansion of PDX biobank repositories with diverse ethnic and rare cancer subtypes for global research access

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient-Derived Xenograft/PDX Model Market, by Type

  • 8.1. Mice Models
  • 8.2. Rat Models

9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 9.1. Gastrointestinal
  • 9.2. Gynecological
  • 9.3. Hematological
  • 9.4. Respiratory
  • 9.5. Urological

10. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 10.1. Ex-vivo
  • 10.2. In-vitro
  • 10.3. In-vivo

11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 11.1. Heterotopic
  • 11.2. Orthotopic
  • 11.3. Subcutaneous

12. Patient-Derived Xenograft/PDX Model Market, by Application

  • 12.1. Basic Cancer Research
  • 12.2. Biomarker Discovery
  • 12.3. Genomic & Molecular Studies
  • 12.4. Personalized Medicine
  • 12.5. Preclinical Drug Evaluation
  • 12.6. Tumor Microenvironment Analysis

13. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 13.1. Academic Research Institutes
  • 13.2. Cancer Research Centers
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Patient-Derived Xenograft/PDX Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Patient-Derived Xenograft/PDX Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Patient-Derived Xenograft/PDX Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abnova Corporation
    • 17.3.2. Altogen Labs
    • 17.3.3. Biocytogen
    • 17.3.4. BioDuro LLC
    • 17.3.5. BioReperia AB
    • 17.3.6. Certis Oncology Solutions
    • 17.3.7. Champions Oncology, Inc.
    • 17.3.8. Charles River Laboratories International, Inc.
    • 17.3.9. Creative Animodel
    • 17.3.10. Creative Biolabs
    • 17.3.11. Crown Bioscience by JSR Corporation
    • 17.3.12. EPO Berlin-Buch GmbH
    • 17.3.13. GemPharmatech Co. Ltd.
    • 17.3.14. Genesis Drug Discovery & Development
    • 17.3.15. Hera Biolabs
    • 17.3.16. HOIST Co.,Ltd.
    • 17.3.17. InnoSer
    • 17.3.18. Inotiv, Inc.
    • 17.3.19. Laboratory Corporation of America Holdings
    • 17.3.20. LIDE Shanghai Biotech, Ltd
    • 17.3.21. Mediford Corporation by PHC Holdings Corporation
    • 17.3.22. Oncodesign Services
    • 17.3.23. Shanghai ChemPartner
    • 17.3.24. Shanghai Medicilon Inc.
    • 17.3.25. TheraIndx Lifesciences Pvt. Ltd.
    • 17.3.26. Urosphere SAS
    • 17.3.27. WuXi AppTec Co., Ltd.
    • 17.3.28. Xentech

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 201